Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/181874
Title: Impact of the Innate Inflammatory Response on ICU Admission and Death in Hospitalized Patients with COVID-19
Author: Monserrat, Jorge
Asunsolo, Angel
Gómez Lahoz, Ana
Ortega, Miguel A.
Gasalla, Jose Maria
Gasulla, Óscar
Fortuny Profitós, Jordi
Mazaira Font, Ferran A.
Teixidó Román, Miguel
Arranz, Alberto
Sanz, José
Muñoz, Benjamin
Arévalo Serrano, Juan
Rodríguez, José Miguel
Martínez Alonso, Carlos
Balomenos, Dimitri
Álvarez Mon, Melchor
Keywords: COVID-19
Citocines
COVID-19
Cytokines
Issue Date: 12-Nov-2021
Publisher: MDPI AG
Abstract: Objective: To describe the capacity of a broad spectrum of cytokines and growth factors to predict ICU admission and/or death in patients with severe COVID-19. Design: An observational, analytical, retrospective cohort study with longitudinal follow-up. Setting: Hospital Universitario Príncipe de Asturias (HUPA). Participants: 287 patients diagnosed with COVID-19 admitted to our hospital from 24 March to 8 May 2020, followed until 31 August 2020. Main outcome measures: Profiles of immune response (IR) mediators were determined using the Luminex Multiplex technique in hospitalized patients within six days of admission by examining serum levels of 62 soluble molecules classified into the three groups: adaptive IR-related cytokines (n = 19), innate inflammatory IR-related cytokines (n = 27), and growth factors (n = 16). Results: A statistically robust link with ICU admission and/or death was detected for increased serum levels of interleukin (IL)-6, IL-15, soluble (s) RAGE, IP10, MCP3, sIL1RII, IL-8, GCSF and MCSF and IL-10. The greatest prognostic value was observed for the marker combination IL-10, IL-6 and GCSF. Conclusions: When severe COVID-19 progresses to ICU admission and/or death there is a marked increase in serum levels of several cytokines and chemokines, mainly related to the patient's inflammatory IR. Serum levels of IL-10, IL-6 and GCSF were most prognostic of the outcome measure.
Note: Reproducció del document publicat a: https://doi.org/10.3390/biomedicines9111675
It is part of: Biomedicines, 2021, vol. 9, num. 11, p. 1675
URI: http://hdl.handle.net/2445/181874
Related resource: https://doi.org/10.3390/biomedicines9111675
ISSN: 2227-9059
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
biomedicines-09-01675-v3.pdf2.05 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons